once monthly glp-1 agonist Injections of an ultra-long-acting investigational led to significant weight loss in people with overweight or obesity, with reductions continuing after a switch to once-monthly dosing, according to the ongoing VESPER ADA 2026 confirmed what many

Objective To determine whether the use of glucagon-like peptide-1 (GLP-1) receptor agonists is associated with an increased risk of suicidal ideation, self-harm, and suicide among patients with type 2 diabetes compared with the use of dipeptidyl peptidase-4 (DPP-4) inhibitors or sodium-glucose cotransporter-2 (SGLT-2) inhibitors

Propensity score matching (PSM) with 1:1 ratio was employed to create balanced cohorts

Summary Integrating emerging mechanistic and clinical observations, this review synthesizes current evidence from a metabolic flux perspective

helps curb food cravings and supports feeling full longer.* CLINICALLY STUDIED NUTRIENTS & BOTANICAL EXTRACTS | GLP-Activate is formulated with clinically researched ingredients that support metabolic wellness and may support natural GLP pathways

Ahead of the Trump administrations planned expansion of Medicare coverage for GLP-1s to treat obesity through temporary models and the availability of Medicares negotiated price for certain GLP-1 products beginning in 2027, this analysis examines CMSs Medicare Part D claims data from 2019 to 2024 to document the increase in the number of beneficiaries being treated with GLP-1 drugs and the growth in Medicare spending and claims for these drugs.

NovoCare Pharmacy provides direct-to-patient, convenient home shipments of all dose strengths of Wegovy at a reduced cost of $499 per month for cash-paying...